Update on Fundamental Mechanisms of Thyroid Cancer.
Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. · 2020
Read Update on Fundamental Mechanisms of Thyroid Cancer. by Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7082927.txt.
Introduction
Prete and co-authors review the fundamental mechanisms of thyroid cancer, in Frontiers in Endocrinology. Thyroid cancer has grown more common over four decades. It comes in distinct types, from papillary and follicular to anaplastic and medullary. Each type runs on different molecular faults.
The review covers the gene changes behind each form. Papillary cancer now splits into BRAF-like and RAS-like subtypes, with different risk levels. RET mutations drive most medullary cases. The authors also weigh the tumor's immune surroundings, better needle biopsy methods, and liquid biopsy from body fluids. These markers now guide diagnosis, risk grading, and drug targets. Readers get a full account of how far the molecular picture has come, and how much of it still has to reach daily care.
Catalog record
| CREATOR | Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Update on Fundamental Mechanisms of Thyroid Cancer By Alessandro Prete, Patricia Borges de Souza, Simona Censi, Marina Muzza, Nicole Nucci, Marialuisa Sponziello Published in: Frontiers in Endocrinology DOI: 10.3389/fendo.2020.00102 ABSTRACT The incidence of thyroid cancer (TC) has increased worldwide over the past four decades. TC is divided into three main histological types: differentiated (papillary and follicular TC), undifferentiated (poorly differentiated and anaplastic TC), and medullary TC, arising from TC cells. This review discusses the molecular mechanisms associated to the pathogenesis of different types of TC and their clinical relevance. In the last years, progresses in the genetic characterization of TC have provided molecular markers for diagnosis, risk stratification, and treatment targets. Recently, papillary TC, the most frequent form of TC, has been reclassified into two molecular subtypes, named BRAF-like and RAS-like, associated to a different range of cancer risks. Similarly, the genetic characterization of follicular TC has been proposed to complement the new histopathological classification in order to estimate the prognosis. New analyses characterized a comprehensive molecular profile of medullary TC, raising the role of RET mutations. More recent evidences suggested that immune microenvironment associated to TC may play a critical role in tumor invasion, with potential immunotherapeutic implications in advanced and metastatic TC. Several types of ancillary approaches have been developed to improve the diagnostic value of fine needle aspiration biopsies in indeterminate thyroid nodules. Finally, liquid biopsy, as a non-invasive diagnostic tool for body fluid genotyping, brings a new prospective of disease and therapy monitoring. Despite all these novelties, much work remains to be done to fully understand the pathogenesis and biological behaviors of the different types of TC and to transfer this knowledge in clinical practice. INTRODUCTION Thyroid cancer (TC) represents the most common endocrine malignancy, accounting for 3.4% of all cancers diagnosed annually (1). The transformation of thyroid follicular cells may result in differentiated or undifferentiated TC, through a multistep process that is the most accepted theory of follicular cell carcinogenesis (2). In this model, distinct molecular alterations have been associated with specific stages, driving progression from well-differentiated to undifferentiated follicular-derived thyroid carcinomas. More recently, the cancer stem-like cells theory has been proposed, according to which phenotypically different cancer cells could be generated by a small subpopulation of stem cells after genetic and epigenetic transformations (3). Differentiated TC, accounting for more than 90% of thyroid malignancies, comprises papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). Poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC) are rare tumors (5 and 1%, respectively) associated with aggressive behavior and short median time of survival (5 years and 6 months, respectively). Differently, medullary thyroid carcinoma (MTC), representing 5% of TC, arises from parafollicular C cells. In the last 30 years, the availability of the genome sequence has produced much progress in elucidating the molecular mechanisms underlying TC (4). TC is a genetically simple disease with a relatively low somatic mutation burden in each tumor. Driver mutations, i.e., mutations that provide a selective growth advantage thus promoting cancer development, are identified in more than 90% of TC (4). The molecular pathogenesis of the majority of TC involves dysregulation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/AKT signaling pathways. MAPK activation is considered to be crucial for PTC initiation, through point mutations of the BRAF and RAS genes or gene fusions of RET/PTC and TRK. On the other hand, PI3K/AKT activation is thought to be critical in FTC initiation and can be triggered by activating mutations in RAS, PIK3CA, and AKT1 as well as by inactivation of PTEN, which negatively regulates this pathway. TC progression and dedifferentiation to PDTC and ATC involves a number of additional mutations affecting other cell signaling pathways, such as p53 and Wnt/β-catenin. More recently, TERT promoter mutations have been described in all the histological TC type, with a significantly higher prevalence in aggressive and undifferentiated tumors, indicating their role in TC progression (Figure 1). Mutations in the RET (Rearranged during transfection) proto-oncogene account for most MTC cases and can occur sporadically or as inherited germline events in the multiple endocrine neoplasia type 2A (MEN2A) and 2B (MEN2B) syndromes. A minority of sporadic MTC are caused by H-, K-, and N-RAS mutations (Table 1). [Figure: The molecular pathogenesis of thyroid cancer involves dysregulation of the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/AKT pathways. Common activating mutations in the MAPK pathway include RET-PTC and NTRK rearrangements, and RAS and BRAF mutations. Common genetic alterations in the PI3K pathway include RAS mutations, PTEN mutations or deletions, PIK3K mutations or amplifications, and AKT1 mutations. PAX8-PPARG fusions are common in FTC. Activation of Wnt/b-catenin pathway, inactivating mutations in TP53, and activating mutations in TERT promoter are frequent in undifferentiated thyroid cancer.] [Table: Distribution and frequency of known somatic mutations in different histotypes of thyroid cancer.] PAPILLARY THYROID CARCINOMA The majority of PTC has an excellent prognosis in terms of long-term survival (>90%) (4, 16), although recurrent disease rates reported are rather high, occurring in 25–35% of patients (4, 17, 18). The clinical challenge relies in the early identification of those patients who need aggressive treatment from the beginning from those who will have an indolent course. At the molecular level, several driver mutations have been associated with PTC malignancy and clinicopathological features, but none has proven useful in directing treatment and determining clinical outcome. Among these, RET rearrangements or point mutations of RAS or BRAF proto-oncogenes have been described and are found in an almost mutually exclusive modality in nearly 70% of PTC (Table 1). These genetic alterations are common in PTC, leading to (constitutively) activation of MAPK or PI3K signaling pathways (19). RET proto-oncogene encodes for a tyrosine kinase receptor and its activation invokes intracellular signaling cascades, leading to gene expression modulation and biological responses. RET/PTC fusion protein maintains the tyrosine kinase domain intact and enables uncontrolled activation of the MAPK signaling cascade (20). RET rearrangement was first reported by Fusco et al. (21), and in the following years, different types of RET/PTC rearrangements have been identified (15). RET/PTC1 and RET/PTC3 are the most common (5), the latter being frequent in post-Chernobyl children due to radiation exposure. The prevalence of RET rearrangements in PTC has varied deeply among studies (2.5–73%) (22, 23) probably due to ethnical and geographical variations as well as to the method used for their identification and genetic heterogeneity, as demonstrated by Zhu et al. (24); recent reports, however, from the Tumor Cancer Genome Atlas (TCGA) in a series of 484 PTC belonging to different ethnic groups, only 6.8% presented RET rearrangements (5). Some reports have indicated RET/PTC1 as being associated with a more favorable prognosis, while RET/PTC3 was associated with a more aggressive and malignant phenotype (25, 26). However, patients harboring these rearrangements usually follow a favorable course, owing to their ability to respond well to radioactive iodine (RAI) therapy (27). It is of interest that in post-Chernobyl TC, other rearrangements have been found: in particular, TRK gene and BRAF gene fusions (28). Recently, NTRK fusions have been reported in some series of advanced cancers and have been proposed as novel targets of cancer therapy (29). BRAF, a member of the raf family of serine/threonine protein kinases, has been shown to be